CN1792366A - Ginkgo leaves dispersion tablets, and its preparing method - Google Patents
Ginkgo leaves dispersion tablets, and its preparing method Download PDFInfo
- Publication number
- CN1792366A CN1792366A CN 200510200696 CN200510200696A CN1792366A CN 1792366 A CN1792366 A CN 1792366A CN 200510200696 CN200510200696 CN 200510200696 CN 200510200696 A CN200510200696 A CN 200510200696A CN 1792366 A CN1792366 A CN 1792366A
- Authority
- CN
- China
- Prior art keywords
- folium ginkgo
- extract
- preparation
- dispersion tablets
- ginkgo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine in the form of dispersing tablet for treating apoplexy, improving memory and resisting against radiation is prepared from ginkgo leaf or its extract and proper additives.
Description
Technical field: the present invention is a kind of ginkgo leaves dispersion tablets and preparation method thereof, belongs to technical field of Chinese medicine.
Technical background: discover that Folium Ginkgo or its extract can remove free radical, blood vessel dilating, the cerebral blood flow increasing amount is improved cerebral ischemia, anoxia, alleviate cerebral edema, antagonism platelet activating factor (PAF) increases the beta Cell of islet excreting insulin, and medium affects the nerves, improve learning and memory and radioprotective etc., in order to the treatment apoplexy, the comprehensive function of stroke patient is recovered obviously to have received significant curative effect with its preparation of making.In order to solve existing Folium Ginkgo general formulation such as tablet, the problem that preparations such as capsule exist, as: disintegrate is slow, stripping is poor, the not high and liquid preparation poor stability of bioavailability, packing, transportation, store inconvenience etc., particularly in order to be convenient to the old man, child or dysphagia patients are taken, pharmacy worker has done number of research projects, also the someone attempts it is developed to tablet formulation, this kind is designed to disperse tablet form, but dispersible tablet need have in 19 ℃～21 ℃ water in the 3min performance of disintegrate fully, and general moulding process is difficult to meet this requirement.So, very be necessary the moulding process of Folium Ginkgo extract is carried out systematic study, develop that a kind of dissolution efficiency is good, bioavailability is high, the reasonable feasible ginkgo leaves dispersion tablets of technology.
Summary of the invention: the objective of the invention is to: a kind of ginkgo leaves dispersion tablets and preparation method thereof is provided, the preparation method of this product has solved the problem that prior art exists, and the product that obtains is particularly suitable for the old people and swallow tablet or capsule inconvenient patient take; The preparation method technology that provides is rationally feasible, product price ratio height, the suitable patient production of taking for a long time, run an enterprise on a commercial.
The present invention constitutes like this: it mainly adds suitable adjuvant by Folium Ginkgo 50～1000g or their extract of corresponding weight portion and is made.
Say accurately: it mainly adds suitable adjuvant by Folium Ginkgo extract 40g and is made;
Adjuvant comprises one or more in calcium sulfate, calcium hydrogen phosphate, polyvidone, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, micropowder silica gel, mannitol, stevioside, radix asparagi sweet extract, pregelatinized Starch, microcrystalline Cellulose, the polyvinylpolypyrrolidone.
The preparation method of this ginkgo leaves dispersion tablets is: get Folium Ginkgo extract, add calcium sulfate, pregelatinized Starch, microcrystalline Cellulose, polyvinylpolypyrrolidone, mixing with 5% starch slurry system soft material, is crossed 18 mesh sieves and is granulated, 60 ℃ of dryings, cross 30 mesh sieve granulate, add micropowder silica gel and Pulvis Talci, mixing, compacting is in blocks, promptly.
Calculate according to weight ratio, the ratio that the consumption of each adjuvant accounts for the prescription total amount is respectively: calcium sulfate 30～50%, pregelatinized Starch 10～25%, microcrystalline Cellulose 5～15%, polyvinylpolypyrrolidone 4～12%, micropowder silica gel 0.5～5%, Pulvis Talci 0.5～5%; We experimental results show that: the pressure of tabletting is between 35～50N.
Among the present invention, Folium Ginkgo extract prepares like this: Folium Ginkgo is pulverized, water or alcoholic solution extract, and merge extractive liquid, is concentrated into an amount of, be added on the macroporous resin column of having handled well, water and different concentration ethanol eluting are collected corresponding eluent successively, reclaim ethanol, drying is pulverized and is promptly got Folium Ginkgo extract.
Specifically: Folium Ginkgo is pulverized, the ethanol that adds 8～10 times 50～80%, heating and refluxing extraction 2～3 times, merge extractive liquid,, decompression recycling ethanol to 60 ℃ mensuration relative density 1.05～1.15, add the hot water dissolving, filter, filtrate is crossed the D-101 macroporous adsorptive resins, with 6～10 times of resinite hydrops flushing impurity, the alcohol desorption of 3～6 times of resin volumes 40～70% of reuse, collect stripping liquid, decompression recycling ethanol to 60 ℃ is measured relative density 1.10～1.20, vacuum drying, pulverize Folium Ginkgo extract.
Compared with prior art, ginkgo leaves dispersion tablets provided by the invention and preparation method thereof, can remove free radical, blood vessel dilating, the cerebral blood flow increasing amount, improve cerebral ischemia, anoxia, alleviate cerebral edema, antagonism platelet activating factor (PAF) increases the beta Cell of islet excreting insulin, medium affects the nerves, improve learning and memory and radioprotective etc., in order to the treatment apoplexy, the comprehensive function of stroke patient is recovered obviously, evident in efficacy, prepared product forms is particularly suitable for the old people and swallow tablet or the inconvenient patient of capsule take.
The present invention finds to reach the quickly disintegrated requirement of dispersible tablet in preparation dispersible tablet formulation process, and it is not enough only using disintegrating agent; Raw material granularity wherein, tabletting pressure all are very crucial: tabletting pressure size influences the porosity of tablet, thereby can influence the disintegrate of tablet and the stripping of medicine, generally speaking, pressure increases, and the porosity of tablet reduces, and disintegration time prolongs, dissolution rate reduces, therefore in the development process of dispersible tablets of Chinese medicine, must find out optimal pressure range by experiment, thereby obtain dissolution rate faster; Chinese medicinal granule chance waterishlogging is sticking in addition also can influence disintegrate significantly.Preparation untoward reaction provided by the invention is little, good effect, cost performance height; But the patients life-time service has solved the problem that prior art exists, and has reached the purpose of invention.
The applicant has carried out a series of experiments, with the supplementary product kind of the preparation technology that selects pharmaceutical preparation provided by the invention, use and consumption, ratio etc.; Guarantee its science, reasonable, feasible; The preparation that obtains has effective therapeutic effect.
Experimental example 1: dispersible tablet Study on Forming
1.1 basic prescription screening
According to principal agent character, through trial test, preliminary selecting with pregelatinized Starch, calcium sulfate or microcrystalline Cellulose serves as to write out a prescription in the basis, is index with the disintegration time, carries out the tabletting test, the results are shown in following table.
| Folium Ginkgo extract (g) | Microcrystalline Cellulose (g) | Pregelatinized Starch (g) | Calcium sulfate (g) | Disintegration time (min) | |
| Prescription 1 | 10 | 0 | 0 | 28 | 25 |
| Prescription 2 | 10 | 0 | 0 | 34 | 19 |
| Prescription 3 | 10 | 28 | 0 | 0 | 23 |
| Prescription 4 | 10 | 34 | 0 | 0 | 16 |
| Prescription 5 | 10 | 0 | 28 | 0 | 13 |
| Prescription 6 | 10 | 0 | 34 | 0 | 7 |
| Prescription 7 | 10 | 0 | 14 | 20 | 11 |
| Prescription 8 | 10 | 14 | 0 | 20 | 14 |
| Prescription 9 | 10 | 20 | 14 | 0 | 12 |
| Prescription 10 | 10 | 5 | 9 | 20 | 8 |
| Prescription 11 | 10 | 9 | 5 | 20 | 9 |
| Prescription 12 | 10 | 5 | 20 | 9 | 10 |
| Prescription 13 | 10 | 20 | 5 | 9 | 13 |
As can be known from the above table, prescription 6 and prescription 10 disintegration times are the shortest, but consider from real cost of production, use the pregelatinized Starch cost higher separately, so select prescription 10 as the basis prescription.
1.2 disintegrating agent is selected
According to the prescription of dispersible tablet, the disintegration time of above-mentioned basis prescription is undesirable, so need to add disintegrating agent.Get Semen Ginkgo extrac 10g, calcium sulfate 20g, pregelatinized Starch 9g, microcrystalline Cellulose 5g respectively, and, select for use polyvinylpolypyrrolidone, carry out the tabletting test, the results are shown in following table as disintegrating agent according to bibliographical information.
Disintegrating agent is selected
| Polyvinylpolypyrrolidone (%) | Disintegration time (second) | ||
| In add | Add | ||
| Prescription 1 | 0 | 0 | 235 |
| Prescription 2 | 5 | 0 | 205 |
| Prescription 3 | 0 | 5 | 197 |
| Prescription 4 | 2.5 | 2.5 | 195 |
| Prescription 5 | 7 | 0 | 135 |
| Prescription 6 | 0 | 7 | 138 |
| Prescription 7 | 3.5 | 3.5 | 140 |
| Prescription 8 | 9 | 0 | 79 |
| Prescription 9 | 0 | 9 | 80 |
| Prescription 10 | 4.5 | 4.5 | 86 |
By above experimental result as can be known, addition, outer addition in adopting, when the polyvinylpolypyrrolidone consumption was 9%, disintegration time was lacked and is more or less the same.But interior addition is easy to use, and tablet just becomes powder once disintegrate; Outer addition tablet not easy disintegrating becomes powder, thus select prescription 8, addition in promptly polyvinylpolypyrrolidone adopts, addition is 9%.
1.3 binding agent is selected
Take by weighing supplementary material by prescription, be divided into 3 equal portions, granulate with purified water, 60% ethanol, 5% starch slurry respectively, granulate, tabletting, the outward appearance and the disintegration time of investigation granule situation, sheet the results are shown in following table.
Binding agent is selected
| Binding agent | The granule situation | The sheet outward appearance | Disintegration time (second) | |
| Sample 1 | Purified water | Easily lump, granule is pine | Unilateral have piebaldism, burr | 89 |
| Sample 2 | 60% ethanol | Granule is pine, and fine powder is many | Unilateral flower, burr slightly | 85 |
| Sample 3 | 5% starch slurry | Granulating efficiency is good, and granule is suitable | Unilateral color even, attractive in appearance | 78 |
By above experimental result as can be known, be that the gained granule was soft after binding agent was granulated with 5% starch slurry, unilateral color even, attractive in appearance, disintegration time is short, so select to granulate with 5% starch slurry.
1.4 the fluidizer consumption is selected
Get the supplementary material of recipe quantity, by method for making granulation, granulate, the gained granule is divided into 4 parts, the consumption that adds micropowder silica gel respectively is 0%, 1%, 2%, 2.5%, mixing, and the disintegration time behind mensuration granule angle of repose and the tabletting the results are shown in Table.
The fluidizer consumption is selected
| Micropowder silica gel consumption (%) | Angle of repose | Disintegration time (second) | |
| Sample 1 | 0 | 47.5° | 80 |
| Sample 2 | 1 | 45.4° | 77 |
| Sample 3 | 2 | 43.9° | 74 |
| Sample 4 | 2.5 | 44.3° | 75 |
Annotate: measure angle of repose and adopt the dump box method, promptly fill granule in rectangular box, its Strobilus Pini degree is suitable, and till box was progressively tilted to granule and begins to flow out, the angle that box tilts was angle of repose.
Above experimental result shows, after adding micropowder silica gel, can significantly improve particulate flowability, and the micropowder silica gel addition is that 2% o'clock mobility of particle is better, so selection micropowder silica gel addition is 2%.
1.5 the selection of granulation, granulate grit number
Get the supplementary material of recipe quantity, behind method for making different meshes sieve series grain, granulate, carry out the tabletting test, outward appearance, disintegration time and the weight differential of observation sheet the results are shown in following table.
The selection of granulation, granulate grit number
| Granulate | Granulate | The sheet outward appearance | Disintegration time | Weight differential | |
| Sample 1 | 16 mesh sieves | 20 mesh sieves | Unilateral apparent piebaldism, burr are arranged | 98 | Defective |
| Sample 2 | 18 mesh sieves | 30 mesh sieves | Unilateral more smooth, attractive in appearance | 79 | Qualified |
By above experimental result as can be known, sample 1 granule is thick partially, unilateral apparent piebaldism behind the tabletting, burr is arranged, and tablet weight variation is defective; Sample 2 granules are suitable, and unilateral more smooth, attractive in appearance behind the tabletting, tablet weight variation is qualified.So select sample 2, promptly granulate 30 mesh sieve granulate with 18 mesh sieves.
1.6 lubricant quantity is selected
Get the supplementary material of recipe quantity,, the gained granule is divided into 3 parts, add Pulvis Talci 0%, 1%, 2% respectively, mixing, tabletting, the outward appearance and the disintegration time of observation sheet, result such as following table by method for making granulation, granulate.
Lubricant quantity is selected
| Lubricant quantity (%) | The sheet outward appearance | Disintegration time (second) | |
| Sample 1 | 0 | Unilateral more coarse | 78 |
| Sample 2 | 1 | Unilateral coarse slightly | 79 |
| Sample 3 | 2 | Unilateral more smooth, attractive in appearance | 81 |
By above result of the test as can be known, unilateral smooth, attractive in appearance when amount of talc is 2%, disintegration time changes not quite simultaneously, is 2% so select the Pulvis Talci addition.
1.7 tabletting pressure is selected
The sample thief granule is an amount of, respectively with different pressure tablettings, measures the disintegration time of sheet, the results are shown in following table.
Tabletting pressure is selected
| Pressure (N) | 30 | 35 | 40 | 45 | 50 | 55 | 60 |
| The sheet outward appearance | Coarse slightly | More smooth | Smooth | Smooth | Smooth | Smooth | Smooth |
| Disintegration time (second) | 20 | 25 | 45 | 75 | 85 | 135 | 190 |
By above experimental result as can be known, the influence that is stressed of the disintegration time of this product is bigger, and when pressure during greater than 50N, disintegration time increases sharply, so the pressure that should control tabletting is between 35～50N.
Experimental example 2: pharmacodynamic experiment
2.1 influence to stasis syndrome rat blood rheological characteristic
60 of rats, male and female half and half, body weight 270 ± 25g.Successive administration 12 days, 1h after the last administration, all the other respectively organize equal sc injection epinephrine 0.8mg/kg, totally twice, two minor tick 4h except that the normal control group.(front and back each 2 hours at interval) immerse 5min in the frozen water, fasting with rat between twice.Femoral artery blood sampling in morning next day, each index of hemorheology is measured in the heparin sodium anticoagulant.
| Group | Dosage (g/kg) | Whole blood viscosity | ||
| Height is cut | In cut | Low cutting | ||
| Normal control | - | 5.22±1.01 | 7.85±1.35 | 14.57±1.52 |
| The model contrast | - | 6.81±1.53 | 8.60±1.76 | 16.33±2.43 |
| Folium Ginkgo tablet group | 6.0 | 6.04±0.62 | 8.14±1.62 | 16.12±4.75 |
| Folium Ginkgo capsule agent group | 6.0 | 5.53±1.70 | 7.92±2.37 | 14.85±3.34 |
| Dispersible tablet group of the present invention | 6.0 | 5.50±0.01 | 7.80±1.53 | 14.69±1.40 |
2.2 platelet aggregation mensuration
Healthy rabbits, male and female are usefulness all, body weight 2～3kg, clear-headed certainly rabbit carotid artery is got blood, is collected in the centrifuge tube of silication with 3.8% sodium citrate anticoagulant, and blood and anticoagulant volume ratio are 9: 1.Respectively through 1000 and the centrifugal 10min of 3000rpm get platelet rich plasma (PRP) and platelet poor plasma (PPP).Press the BornShi turbidimetry, with BS-631 type autobalance platelet aggregation instrument, PRP is hatched 15min with the medicinal liquid of variable concentrations earlier, adds derivants such as ADP, AA or PAF again, and the waveform of record platelet aggregation also calculates maximum agglutination rate, the results are shown in following table.Platelet aggregation inhibition rate is calculated as follows:
Assemble suppression ratio (%)=(1-delivery tube aggregation rate/control tube aggregation rate) * 100%
Influence (the unit: %) of the platelet aggregation rate that different derivants are brought out
| The dense Medicine ρ of medicine (g/L) | ADP ρ(3μmol/L) | AA ρ(0.35mmol/L) | PAF ρ(7.2nmol/L) | |
| Matched group | - | 57.0±2.5 | 67.6±1.5 | 56.4±1.2 |
| The tablet group | 2.0 | 38.3±6.4 | 27.4±2.6 | 46.3±2.6 |
| The capsule group | 2.0 | 34.5±2.3 | 25.6±1.5 | 45.4±5.6 |
| Dispersible tablet group of the present invention | 2.0 | 29.0±2.9 | 22.8±3.1 | 39.6±1.3 |
The result shows: preparation of the present invention is obvious for the effect of stasis syndrome rat blood rheological characteristic, rabbit platelet aggregation, is not less than Folium Ginkgo and Folium Ginkgo capsule.
2.3 to the metabolic influence of blood glucose
2.3.1 animal grouping and processing
Get male SD rat, body weight 180～220g is divided into normal control group, model group, Folium Ginkgo group, Folium Ginkgo capsule group and dispersible tablet group of the present invention at random, every group each 10.Each is organized rat and (is dissolved in the 0.1mmol/L citric acid buffer, pH=4.0) by 50mg/kg intraperitoneal injection streptozotocin behind fasting 12h.Injection back 72h surveys blood glucose, and blood glucose 〉=13.8mmol/L is the model success.Folium Ginkgo group, Folium Ginkgo capsule group and gingko leaf dispersible tablet group, each is organized rat and feeds Folium Ginkgo, Folium Ginkgo capsule and gingko leaf dispersible tablet by 7mg/ (kgd) dosage respectively, every day 1 time, continuous 5 weeks.
2.3.2 the preparation of serum, blood plasma
Three groups of all capable femoral artery sacrificed by exsanguination of rats are got blood 3ml, and room temperature is solidified about 1h, and the centrifugal 15min separation of serum of 3000r/min places-30 ℃ of freezing preservations of cryogenic refrigerator, blood glucose to be measured, insulin.
2.3.3 the blood index detects
With determination of glucose oxidase serum glucose concentration, serum measured by radioimmunoassay insulin.
2.3.4 result
Rat blood sugar, insulin are relatively
| Group | N/ only | GLU/(mmol/L) | INS/(mIU/L) |
| The normal control group | 10 | 5.86±0.85 | 25.48±1.85 |
| Model group | 10 | 28.41±2.75 | 14.24±2.50 |
| The Folium Ginkgo group | 10 | 20.54±7.37 | 17.65±3.24 |
| The Folium Ginkgo capsule group | 10 | 20.26±7.42 | 17.52±3.87 |
| Dispersible tablet group of the present invention | 10 | 19.32±6.84 | 18.71±4.15 |
The result shows: dispersible tablet of the present invention has hypoglycemic activity to diabetes rat, and serum insulin levels is raise,, and effect is better than Folium Ginkgo and Folium Ginkgo capsule, illustrates that dispersible tablet of the present invention has the good curing effect to diabetes.
Concrete embodiment:
Embodiments of the invention 1: Folium Ginkgo extract 40g
Get Folium Ginkgo extract, add calcium sulfate 80g, pregelatinized Starch 36g, microcrystalline Cellulose 20g, polyvinylpolypyrrolidone 16g, mixing, with 5% starch slurry system soft material, cross 18 mesh sieves and granulate 60 ℃ of dryings, cross 30 mesh sieve granulate, add micropowder silica gel 4g and Pulvis Talci 4g, mixing, tabletting, the pressure of tabletting promptly gets dispersible tablet between 35～50N, oral, one time 2,3 times on the one.
Embodiments of the invention 2: Folium Ginkgo extract 2g
Add the 1g calcium hydrogen phosphate, the 0.3g low-substituted hydroxypropyl cellulose, the 0.3g crospolyvinylpyrrolidone is used 5% polyvidone, and the system soft material adds 1% stevioside, mix homogeneously, one-shot formula tablet machine, 2 grades of pressure tablettings promptly get dispersible tablet.
Embodiments of the invention 3: Folium Ginkgo extract 10g
Add amylum pregelatinisatum 10g, the swollen shallow lake P of 3% dimension, system soft material, cross 20 mesh sieves and granulate 60 ℃ of oven dry, 20 order granulate, add the swollen shallow lake P of 2% dimension, 8% microcrystalline Cellulose, 8% crospolyvinylpyrrolidone, 4% radix asparagi sweet extract, mix homogeneously, one-shot formula tablet machine, 2 grades of pressure tablettings promptly, promptly get dispersible tablet.
Embodiments of the invention 4: Folium Ginkgo extract 50g
Get Folium Ginkgo extract, add 12% microcrystalline Cellulose, 4% micropowder silica gel, 10% carboxymethyl starch sodium, mix homogeneously, tabletting promptly, promptly gets dispersible tablet.
Embodiments of the invention 5: Folium Ginkgo 40g
Add 40g mannitol, 8% crospolyvinylpyrrolidone, 2% starch slurry, the system soft material is crossed 20 mesh sieves and is granulated, 60 ℃ of oven dry, 20 order granulate add 9% microcrystalline Cellulose, mix homogeneously, tabletting promptly, promptly gets dispersible tablet.
Embodiments of the invention 6: Folium Ginkgo 1000g
Get Folium Ginkgo, pulverize, extract 3 times with 8 times of amount 60% alcohol heating reflux, merge extractive liquid,, relative density is 1.05～1.10 when reclaiming ethanol and being concentrated into 60 ℃, adds 2 times of water gaging heating for dissolving, filter, filtrate is added on the AB-8 type macroporous adsorptive resins of having handled well, successively water and 10% ethanol elution impurity, reuse 50% ethanol elution, collect 50% alcoholic acid eluent, reclaim ethanol, be condensed into thick paste, vacuum drying, pulverize Folium Ginkgo extract.
Embodiments of the invention 7: Folium Ginkgo 500g
Get Folium Ginkgo, pulverize, measured 50% soak with ethanol 12 hours with 15 times, speed percolation with 10ml/min extracts then, merge extractive liquid,, and relative density is 1.05～1.10 when reclaiming ethanol and being concentrated into 60 ℃, add 3 times of water heating for dissolving, filter, filtrate is added on the D-101 type macroporous adsorptive resins of having handled well, with 8 times of resinite hydrops flushings, 6 times of resin volume 70% ethanol elutions of reuse, collect corresponding eluent, reclaim ethanol, vacuum drying gets Folium Ginkgo extract.The content of total flavonoid glycoside is calculated as 28.16% by (quercetin content+kaempferide content+isorhamnetin content) * 2.51 formula in the extract after testing; Extract adopts the calculating of external standard two-point method logarithmic equation to contain terpene lactone and counts 7.32% with bilobalide, ginkalide A, ginkalide B and ginkalide C content sum.
Embodiments of the invention 8: Folium Ginkgo 800g
Getting Folium Ginkgo pulverizes, adding 8 times of decoctings boils 3 times, each 1 hour, merge decoction liquor, filter, relative density was 1.05～1.10 when filtrate was concentrated into 60 ℃, add the equivalent ethyl acetate extraction 5 times, combined ethyl acetate liquid, decompression and solvent recovery, the concentrated solution vacuum drying, pulverize Folium Ginkgo extract.
Folium Ginkgo extract among the above embodiment can be with commercially available or make by the inventive method, content limit be total flavonoids more than or equal to 24%, terpene lactone is more than or equal to 6%.
Claims (8)
1. ginkgo leaves dispersion tablets, it is characterized in that: it mainly adds suitable adjuvant by Folium Ginkgo 50～1000g or their extract of corresponding weight portion and is made.
2. according to the described ginkgo leaves dispersion tablets of claim 1, it is characterized in that: it mainly adds suitable adjuvant by Folium Ginkgo extract 40g and is made.
3. according to claim 1 or 2 described ginkgo leaves dispersion tablets, it is characterized in that: adjuvant comprises one or more in calcium sulfate, calcium hydrogen phosphate, polyvidone, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, micropowder silica gel, mannitol, stevioside, radix asparagi sweet extract, pregelatinized Starch, microcrystalline Cellulose, the polyvinylpolypyrrolidone.
4. according to the preparation method of claim 1 or 2 any described ginkgo leaves dispersion tablets, it is characterized in that: get Folium Ginkgo extract, add calcium sulfate, pregelatinized Starch, microcrystalline Cellulose, polyvinylpolypyrrolidone, mixing, with 5% starch slurry system soft material, cross 18 mesh sieves and granulate, 60 ℃ of dryings are crossed 30 mesh sieve granulate, add micropowder silica gel and Pulvis Talci, mixing, compacting is in blocks, promptly.
5. according to the preparation method of the described ginkgo leaves dispersion tablets of claim 4, it is characterized in that: calculate according to weight ratio, the part by weight that the consumption of each adjuvant accounts for the prescription total amount is respectively: calcium sulfate 30～50%, pregelatinized Starch 10～25%, microcrystalline Cellulose 5～15%, polyvinylpolypyrrolidone 4～12%, micropowder silica gel 0.5～5%, Pulvis Talci 0.5～5%.
6. according to the preparation method of the described ginkgo leaves dispersion tablets of claim 4, it is characterized in that: the pressure of tabletting is between 35～50N.
7. according to the preparation method of the described ginkgo leaves dispersion tablets of claim 4, it is characterized in that: Folium Ginkgo extract is preparation like this: Folium Ginkgo is pulverized, water or alcoholic solution extract, and merge extractive liquid, is concentrated into an amount of, be added on the macroporous resin column of having handled well, water and different concentration ethanol eluting are collected corresponding eluent successively, reclaim ethanol, drying is pulverized and is promptly got Folium Ginkgo extract.
8. according to the preparation method of the described Folium Ginkgo extract of claim 7, it is characterized in that: Folium Ginkgo is pulverized, the ethanol that adds 8～10 times 50～80%, heating and refluxing extraction 2～3 times, merge extractive liquid,, decompression recycling ethanol to 60 ℃ mensuration relative density 1.05～1.15, add the hot water dissolving, filter, filtrate is crossed the D-101 macroporous adsorptive resins, with 6～10 times of resinite hydrops flushing impurity, the alcohol desorption of 3～6 times of resin volumes 40～70% of reuse is collected stripping liquid, decompression recycling ethanol to 60 ℃ mensuration relative density 1.10～1.20, vacuum drying, pulverize Folium Ginkgo extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510200696 CN1792366A (en) | 2004-11-15 | 2005-11-14 | Ginkgo leaves dispersion tablets, and its preparing method |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410081274.4 | 2004-11-15 | ||
| CN 200410081274 CN1634378A (en) | 2004-11-15 | 2004-11-15 | Ginkgo leaf dispersable tablet and preparation method thereof |
| CN 200510200696 CN1792366A (en) | 2004-11-15 | 2005-11-14 | Ginkgo leaves dispersion tablets, and its preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1792366A true CN1792366A (en) | 2006-06-28 |
Family
ID=36804139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510200696 Pending CN1792366A (en) | 2004-11-15 | 2005-11-14 | Ginkgo leaves dispersion tablets, and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1792366A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877130A (en) * | 2013-09-17 | 2014-06-25 | 狄留庆 | Chinese medicinal composition for treating ischemic cerebral paralysis, application thereof to preparation of oral preparation and preparation of Chinese medicinal composition |
| CN103893293A (en) * | 2014-04-10 | 2014-07-02 | 中国人民解放军空军航空医学研究所 | Compound folium ginkgo preparation for improving learning and memory abilities |
| CN103961382A (en) * | 2014-04-24 | 2014-08-06 | 张风华 | Compound folium ginkgo syrup preparation formula promoting child growth and intellect development |
-
2005
- 2005-11-14 CN CN 200510200696 patent/CN1792366A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877130A (en) * | 2013-09-17 | 2014-06-25 | 狄留庆 | Chinese medicinal composition for treating ischemic cerebral paralysis, application thereof to preparation of oral preparation and preparation of Chinese medicinal composition |
| CN103893293A (en) * | 2014-04-10 | 2014-07-02 | 中国人民解放军空军航空医学研究所 | Compound folium ginkgo preparation for improving learning and memory abilities |
| CN103893293B (en) * | 2014-04-10 | 2016-06-15 | 中国人民解放军空军航空医学研究所 | A kind of compound gingko leaf preparation improving learning and memory function |
| CN103961382A (en) * | 2014-04-24 | 2014-08-06 | 张风华 | Compound folium ginkgo syrup preparation formula promoting child growth and intellect development |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101961364B (en) | Effective part of chicory or jerusalem artichoke and preparation thereof | |
| WO2015081703A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
| CN100477985C (en) | Dispersible tablet for clearing away heat of brain and heart and preparation process thereof | |
| CN101966316B (en) | Gujin pill pellet and preparation method thereof | |
| CN1792366A (en) | Ginkgo leaves dispersion tablets, and its preparing method | |
| CN1226033C (en) | Method for preparing traditional Chinese medicine concentrated pill | |
| CN1709451A (en) | Underleaf pearl formulation for treatig liver-gallbladder diseases and its preparing method | |
| CN1329062C (en) | Method for preparing medicine for treating cataclasis and soft tissue injury | |
| CN1772084A (en) | Tongshu oral cavity refreshing tablet and its prepn | |
| CN114288256A (en) | Preparation method of sugar-free tablet for treating enteritis | |
| CN1745809A (en) | Liuwei Dihuang effervescent tablet and its preparation thereof | |
| CN1806813A (en) | Orally quick-acting tablet of ginseng stem leaf saponin including orally disintegrating tablet and dispersible tablet and method for preparing the same | |
| CN100506219C (en) | Notoginseng hemostatic and its preparing method | |
| CN1634378A (en) | Ginkgo leaf dispersable tablet and preparation method thereof | |
| CN101077364A (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN1709430A (en) | Medicinal bock greenbrier rhizome micro pill and its preparing method | |
| CN104435447B (en) | A kind of Ge Shan blood fat reducing slow releasing preparation and preparation method thereof | |
| CN1990012A (en) | Three-yellow dispersed tablet | |
| CN1861158A (en) | Dispersing tablets of Liuwei-dihuang extract or its add-substract components, and its prepn. method | |
| CN1194748C (en) | Medicine for treating hypertension and preparation method | |
| CN1594315A (en) | Novel process for preparation of silybum mariamum extractive methylglucamine | |
| CN103655727A (en) | Condensed pill prepared from ligustrum lucidum and radix astragali and capable of reinforcing healthy qi, and preparation method thereof | |
| CN101045154A (en) | Method for preventing traditional Chinese medicine extract powder from being moisture absorption | |
| CN1915266A (en) | Medicinal composition, preparation method and quality control method | |
| CN1927350A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |